PMID- 35005866
OWN - NLM
STAT- MEDLINE
DCOM- 20220112
LR  - 20220729
IS  - 1545-9616 (Print)
IS  - 1545-9616 (Linking)
VI  - 21
IP  - 1
DP  - 2022 Jan 1
TI  - Consumer Perspectives on and Utilization of Medical Cannabis to Treat 
      Dermatologic Conditions.
PG  - 31-36
LID - 10.36849/JDD.2022.6540 [doi]
AB  - BACKGROUND: Access to medical cannabis products (MCPs) has rapidly increased 
      though literature on consumer behaviors and attitudes with regards to 
      dermatologic use is limited. OBJECTIVE: We sought to address the gap of knowledge 
      regarding consumer utilization and perspectives surrounding MCPs for dermatologic 
      indications. METHODS: A survey was emailed via SurveyMonkey’s platform to 
      adult users of their rewards panel asking about usage patterns and beliefs 
      regarding MCP use to treat dermatologic conditions. RESULTS: 504 of 700 survey 
      invitations sent out were completed (72% response rate). 17.6% of respondents 
      used an over-the-counter (OTC) cannabis product without dermatologist 
      recommendation to treat a skin condition [most common indications: acne (28.4%) 
      and psoriasis (26.1%)]. Of those who had seen a dermatologist, 15.3% used an OTC 
      product [most common indications: psoriasis (32%) and rosacea (30%)] and 7.8% 
      used an MCP which required a Department of Health-approved card per their 
      dermatologist’s recommendations [most common indications: acne (68%) and 
      psoriasis (28%)]. 11.8% of respondents were not comfortable seeing a 
      dermatologist who recommended MCPs. LIMITATIONS: Limitations include small sample 
      size as well as selection bias. CONCLUSION: Consumers are interested in and are 
      using MCPs for dermatologic indications, most commonly for inflammatory skin 
      disorders. Targeted education for dermatologists is recommended. J Drugs 
      Dermatol. 2022;21(1):31-36. doi:10.36849/JDD.6540.
FAU - Yeroushalmi, Samuel
AU  - Yeroushalmi S
FAU - Nemirovsky, Daniel
AU  - Nemirovsky D
FAU - Mamlouk, Mira
AU  - Mamlouk M
FAU - Feldman, Dovid
AU  - Feldman D
FAU - Nelson, Kamaria
AU  - Nelson K
FAU - Sparks, Andrew
AU  - Sparks A
FAU - Friedman, Adam
AU  - Friedman A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Drugs Dermatol
JT  - Journal of drugs in dermatology : JDD
JID - 101160020
RN  - 0 (Medical Marijuana)
RN  - 0 (Nonprescription Drugs)
SB  - IM
MH  - *Acne Vulgaris
MH  - Adult
MH  - Humans
MH  - *Medical Marijuana
MH  - Nonprescription Drugs
MH  - *Rosacea
MH  - Skin Care
EDAT- 2022/01/11 06:00
MHDA- 2022/01/13 06:00
CRDT- 2022/01/10 10:20
PHST- 2022/01/10 10:20 [entrez]
PHST- 2022/01/11 06:00 [pubmed]
PHST- 2022/01/13 06:00 [medline]
AID - S1545961622P0031X [pii]
AID - 10.36849/JDD.2022.6540 [doi]
PST - ppublish
SO  - J Drugs Dermatol. 2022 Jan 1;21(1):31-36. doi: 10.36849/JDD.2022.6540.